- Home
- BRKR vs RGEN Comparison
BRKR vs RGEN Comparison
Compare BRKR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRKR | RGEN |
|---|---|---|
| Founded | 1960 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.6B |
| IPO Year | 2000 | 1995 |
Fundamental Metrics
Financial Performance| Metric | BRKR | RGEN |
|---|---|---|
| Price | $53.94 | $131.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $48.54 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | 0.02 | ★ 0.15 |
| Revenue | ★ $1,895,600,000.00 | $141,236,000.00 |
| Revenue This Year | $6.30 | $14.30 |
| Revenue Next Year | $3.81 | $14.52 |
| P/E Ratio | $2,759.00 | ★ $888.87 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $28.53 | $100.99 |
| 52 Week High | $64.54 | $175.77 |
Technical Indicators
Market Signals| Indicator | BRKR | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 63.10 |
| Support Level | $33.52 | $130.40 |
| Resistance Level | $54.86 | $172.45 |
| Average True Range (ATR) | 3.38 | 5.86 |
| MACD | -0.47 | 1.69 |
| Stochastic Oscillator | 45.92 | 83.03 |
Price Performance
Historical ComparisonAbout BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.